(NVMI) Nova - Overview
Stock: Metrology Platforms, Dimensional Systems, Films Systems, Chemical Metrology
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 56.0% |
| Relative Tail Risk | -4.32% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.28 |
| Alpha | 59.76 |
| Character TTM | |
|---|---|
| Beta | 1.833 |
| Beta Downside | 1.716 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.79% |
| CAGR/Max DD | 1.77 |
Description: NVMI Nova January 06, 2026
Nova Ltd. (NASDAQ:NVMI) designs, develops, produces, and sells advanced process-control metrology systems that enable semiconductor manufacturers to monitor and optimize critical steps such as lithography, etch, deposition, CMP, and advanced packaging. The company operates globally, with key sales regions in Taiwan, the United States, China, Korea, and other international markets, and serves logic, foundry, memory, and packaging customers as well as equipment makers.
The product suite spans dimensional metrology, film-thickness measurement, and chemical metrology platforms, providing real-time feedback for process windows across the semiconductor fab. By targeting high-mix, low-volume nodes and emerging packaging technologies (e.g., chip-on-wafer and fan-out wafer-level packaging), Nova positions itself in a niche that complements larger equipment OEMs.
Recent financials show the company on an upward trajectory: FY 2023 revenue reached approximately $340 million, up ~12% YoY, with a gross margin of ~55% and an operating cash-flow conversion of 85%. The order backlog at year-end was roughly $500 million, indicating strong demand ahead. Macro-level, global semiconductor fab-equipment spending is projected to grow ~8% CAGR through 2028, driven by AI-centric chips, 3-nm and finer nodes, and the shift toward advanced packaging-trends that directly boost demand for precision metrology solutions.
For a deeper, data-driven perspective on Nova’s valuation dynamics, you may find the analytics on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 245.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -3.40 > 1.0 |
| NWC/Revenue: 132.5% < 20% (prev 86.35%; Δ 46.16% < -1%) |
| CFO/TA 0.11 > 3% & CFO 254.6m > Net Income 245.0m |
| Net Debt (362.1m) to EBITDA (278.1m): 1.30 < 3 |
| Current Ratio: 4.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.5m) vs 12m ago 0.72% < -2% |
| Gross Margin: 57.10% > 18% (prev 0.57%; Δ 5653 % > 0.5%) |
| Asset Turnover: 46.84% > 50% (prev 45.89%; Δ 0.96% > 0%) |
| Interest Coverage Ratio: 159.7 > 6 (EBITDA TTM 278.1m / Interest Expense TTM 1.61m) |
Altman Z'' 6.37
| A: 0.49 (Total Current Assets 1.45b - Total Current Liabilities 315.5m) / Total Assets 2.31b |
| B: 0.35 (Retained Earnings 798.1m / Total Assets 2.31b) |
| C: 0.14 (EBIT TTM 257.7m / Avg Total Assets 1.82b) |
| D: 1.03 (Book Value of Equity 1.17b / Total Liabilities 1.14b) |
| Altman-Z'' Score: 6.37 = AAA |
Beneish M -2.67
| DSRI: 0.91 (Receivables 144.9m/114.4m, Revenue 852.7m/611.8m) |
| GMI: 1.01 (GM 57.10% / 57.39%) |
| AQI: 1.25 (AQ_t 0.31 / AQ_t-1 0.25) |
| SGI: 1.39 (Revenue 852.7m / 611.8m) |
| TATA: -0.00 (NI 245.0m - CFO 254.6m) / TA 2.31b) |
| Beneish M-Score: -2.67 (Cap -4..+1) = A |
What is the price of NVMI shares?
Over the past week, the price has changed by +0.46%, over one month by +17.54%, over three months by +46.47% and over the past year by +81.25%.
Is NVMI a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NVMI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 393.8 | -14.4% |
| Analysts Target Price | 393.8 | -14.4% |
| ValueRay Target Price | 746.4 | 62.3% |
NVMI Fundamental Data Overview February 03, 2026
P/E Forward = 43.1034
P/S = 15.9209
P/B = 11.5942
Revenue TTM = 852.7m USD
EBIT TTM = 257.7m USD
EBITDA TTM = 278.1m USD
Long Term Debt = 730.7m USD (from longTermDebt, last quarter)
Short Term Debt = 98.1m USD (from shortTermDebt, last quarter)
Debt = 883.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 362.1m USD (from netDebt column, last quarter)
Enterprise Value = 13.37b USD (13.58b + Debt 883.7m - CCE 1.09b)
Interest Coverage Ratio = 159.7 (Ebit TTM 257.7m / Interest Expense TTM 1.61m)
EV/FCF = 58.00x (Enterprise Value 13.37b / FCF TTM 230.5m)
FCF Yield = 1.72% (FCF TTM 230.5m / Enterprise Value 13.37b)
FCF Margin = 27.04% (FCF TTM 230.5m / Revenue TTM 852.7m)
Net Margin = 28.73% (Net Income TTM 245.0m / Revenue TTM 852.7m)
Gross Margin = 57.10% ((Revenue TTM 852.7m - Cost of Revenue TTM 365.8m) / Revenue TTM)
Gross Margin QoQ = 56.73% (prev 57.84%)
Tobins Q-Ratio = 5.79 (Enterprise Value 13.37b / Total Assets 2.31b)
Interest Expense / Debt = 0.18% (Interest Expense 1.61m / Debt 883.7m)
Taxrate = 16.32% (12.0m / 73.4m)
NOPAT = 215.7m (EBIT 257.7m * (1 - 16.32%))
Current Ratio = 4.58 (Total Current Assets 1.45b / Total Current Liabilities 315.5m)
Debt / Equity = 0.75 (Debt 883.7m / totalStockholderEquity, last quarter 1.17b)
Debt / EBITDA = 1.30 (Net Debt 362.1m / EBITDA 278.1m)
Debt / FCF = 1.57 (Net Debt 362.1m / FCF TTM 230.5m)
Total Stockholder Equity = 1.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.46% (Net Income 245.0m / Total Assets 2.31b)
RoE = 23.46% (Net Income TTM 245.0m / Total Stockholder Equity 1.04b)
RoCE = 14.52% (EBIT 257.7m / Capital Employed (Equity 1.04b + L.T.Debt 730.7m))
RoIC = 38.16% (NOPAT 215.7m / Invested Capital 565.2m)
WACC = 11.91% (E(13.58b)/V(14.46b) * Re(12.67%) + D(883.7m)/V(14.46b) * Rd(0.18%) * (1-Tc(0.16)))
Discount Rate = 12.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.70%
[DCF Debug] Terminal Value 69.64% ; FCFF base≈209.8m ; Y1≈258.8m ; Y5≈440.7m
Fair Price DCF = 126.8 (EV 4.12b - Net Debt 362.1m = Equity 3.76b / Shares 29.7m; r=11.91% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 9.23 | EPS CAGR: -46.95% | SUE: -4.0 | # QB: 0
Revenue Correlation: 83.89 | Revenue CAGR: 17.80% | SUE: 0.72 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.16 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=8
EPS next Year (2026-12-31): EPS=9.73 | Chg30d=+0.106 | Revisions Net=+1 | Growth EPS=+12.1% | Growth Revenue=+11.9%